FILANA THERAPEUTICS INC
FLNANASDAQ🏆 #4469 by market capUS Equity
$0.64▼ $0.00 (−0.48%)
Pre-market · at closeTrack FLNA
Get earnings, price moves & breaking news on Telegram
24h▼ 0.5%
7d▼ 1.0%
14d▼ 16.0%
30d▼ 31.0%
ytd▼ 67.3%
1y▼ 81.1%
🏦Market Cap
$31M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
17.8%
Healthy
⚖️P/S Ratio
0.8x
Cheap
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $0.64 – $0.65
- 52-Week Range
- $0.60 – $2.27
- Volume (shares)
- 769
- Avg Volume (shares)
- —
- Shares Outstanding
- 48.3M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 0.8x
- EPS (TTM)
- $-0.88
- Dividend Yield
- —
- Dilution (1yr)
- −99.0%
FILANA THERAPEUTICS INC
FLNAFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$95M▼ −32.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$33M▼ −71.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
48.3M▼ −99.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$96M▼ −$33M YoY
StockOtter · stockotter.spaceAbout FILANA THERAPEUTICS INC
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.